Does the media prefer NEO or FLGT?

In the previous week, NeoGenomics had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 3 mentions for NeoGenomics and 2 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.30 beat NeoGenomics' score of 0.62 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, PGNY or FLGT?

Progyny has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.53 $58.52M $0.92 27.88 Fulgent Genetics $322.67M 1.70 -$60.51M -$2.82 N/A

Is PGNY or FLGT more profitable?

Progyny has a net margin of 6.00% compared to Fulgent Genetics' net margin of -26.05%. Progyny's return on equity of 15.98% beat Fulgent Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.00% 15.98% 10.65% Fulgent Genetics -26.05% -4.93% -4.50%

Does the media prefer PGNY or FLGT?

In the previous week, Progyny had 8 more articles in the media than Fulgent Genetics. MarketBeat recorded 10 mentions for Progyny and 2 mentions for Fulgent Genetics. Progyny's average media sentiment score of 1.35 beat Fulgent Genetics' score of 1.30 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FLGT or GRDN?

In the previous week, Fulgent Genetics had 1 more articles in the media than Guardian Pharmacy Services. MarketBeat recorded 2 mentions for Fulgent Genetics and 1 mentions for Guardian Pharmacy Services. Fulgent Genetics' average media sentiment score of 1.30 beat Guardian Pharmacy Services' score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Guardian Pharmacy Services 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor FLGT or AGL?

In the previous week, Agilon Health had 2 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for Agilon Health and 2 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.30 beat Agilon Health's score of 0.50 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agilon Health 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, INNV or FLGT?

InnovAge has higher revenue and earnings than Fulgent Genetics. InnovAge is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InnovAge $853.70M 1.74 -$30.31M -$0.09 N/A Fulgent Genetics $322.67M 1.70 -$60.51M -$2.82 N/A

Does the media prefer INNV or FLGT?

In the previous week, InnovAge had 7 more articles in the media than Fulgent Genetics. MarketBeat recorded 9 mentions for InnovAge and 2 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.30 beat InnovAge's score of 1.16 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InnovAge 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Fulgent Genetics (FLGT) Competitors

$19.90 -0.02 (-0.10%)

As of 08/21/2026 04:00 PM Eastern

Compare

FLGT vs. NEO, PGNY, GRDN, AGL, and INNV

Should you buy Fulgent Genetics stock or one of its competitors? Fulgent Genetics's main competitors and comparable companies include NeoGenomics (NEO), Progyny (PGNY), Guardian Pharmacy Services (GRDN), Agilon Health (AGL), and InnovAge (INNV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Fulgent Genetics compare to NeoGenomics?

NeoGenomics (NASDAQ:NEO) and Fulgent Genetics (NASDAQ:FLGT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

NeoGenomics has a net margin of -6.77% compared to Fulgent Genetics' net margin of -26.05%. NeoGenomics' return on equity of -1.99% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

NeoGenomics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

NeoGenomics currently has a consensus target price of $16.71, indicating a potential downside of 1.56%. Fulgent Genetics has a consensus target price of $27.50, indicating a potential upside of 38.19%. Given Fulgent Genetics' higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 1.1% of NeoGenomics shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fulgent Genetics has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	3.00	-$108.03M	-$0.40	N/A
Fulgent Genetics	$322.67M	1.70	-$60.51M	-$2.82	N/A

In the previous week, NeoGenomics had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 3 mentions for NeoGenomics and 2 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.30 beat NeoGenomics' score of 0.62 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NeoGenomics beats Fulgent Genetics on 12 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Progyny?

Progyny (NASDAQ:PGNY) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Progyny has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Progyny has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.53	$58.52M	$0.92	27.88
Fulgent Genetics	$322.67M	1.70	-$60.51M	-$2.82	N/A

94.9% of Progyny shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Progyny had 8 more articles in the media than Fulgent Genetics. MarketBeat recorded 10 mentions for Progyny and 2 mentions for Fulgent Genetics. Progyny's average media sentiment score of 1.35 beat Fulgent Genetics' score of 1.30 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny presently has a consensus price target of $33.91, indicating a potential upside of 32.20%. Fulgent Genetics has a consensus price target of $27.50, indicating a potential upside of 38.19%. Given Fulgent Genetics' higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Progyny has a net margin of 6.00% compared to Fulgent Genetics' net margin of -26.05%. Progyny's return on equity of 15.98% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Summary

Progyny beats Fulgent Genetics on 14 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Fulgent Genetics (NASDAQ:FLGT) and Guardian Pharmacy Services (NYSE:GRDN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Guardian Pharmacy Services has a net margin of 4.50% compared to Fulgent Genetics' net margin of -26.05%. Guardian Pharmacy Services' return on equity of 29.97% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Guardian Pharmacy Services	4.50%	29.97%	16.18%

Fulgent Genetics presently has a consensus target price of $27.50, suggesting a potential upside of 38.19%. Guardian Pharmacy Services has a consensus target price of $43.83, suggesting a potential upside of 15.66%. Given Fulgent Genetics' higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than Guardian Pharmacy Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Guardian Pharmacy Services	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Guardian Pharmacy Services has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.70	-$60.51M	-$2.82	N/A
Guardian Pharmacy Services	$1.45B	1.30	$49.22M	$1.03	36.80

Fulgent Genetics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Guardian Pharmacy Services has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

In the previous week, Fulgent Genetics had 1 more articles in the media than Guardian Pharmacy Services. MarketBeat recorded 2 mentions for Fulgent Genetics and 1 mentions for Guardian Pharmacy Services. Fulgent Genetics' average media sentiment score of 1.30 beat Guardian Pharmacy Services' score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Guardian Pharmacy Services	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

48.1% of Fulgent Genetics shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by insiders. Comparatively, 33.0% of Guardian Pharmacy Services shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Guardian Pharmacy Services beats Fulgent Genetics on 9 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Agilon Health?

Fulgent Genetics (NASDAQ:FLGT) and Agilon Health (NYSE:AGL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

48.1% of Fulgent Genetics shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 2.5% of Agilon Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Agilon Health had 2 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for Agilon Health and 2 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.30 beat Agilon Health's score of 0.50 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilon Health	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fulgent Genetics currently has a consensus price target of $27.50, suggesting a potential upside of 38.19%. Agilon Health has a consensus price target of $91.30, suggesting a potential downside of 5.21%. Given Fulgent Genetics' higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Agilon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Agilon Health	2 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.21

Fulgent Genetics has higher earnings, but lower revenue than Agilon Health. Fulgent Genetics is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.70	-$60.51M	-$2.82	N/A
Agilon Health	$5.93B	0.27	-$391.35M	-$14.27	N/A

Fulgent Genetics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Agilon Health has a beta of 3.01, meaning that its share price is 201% more volatile than the broader market.

Agilon Health has a net margin of -3.92% compared to Fulgent Genetics' net margin of -26.05%. Fulgent Genetics' return on equity of -4.93% beat Agilon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Agilon Health	-3.92%	-119.38%	-16.85%

Summary

Fulgent Genetics beats Agilon Health on 9 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to InnovAge?

InnovAge (NASDAQ:INNV) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

InnovAge currently has a consensus price target of $10.00, indicating a potential downside of 8.76%. Fulgent Genetics has a consensus price target of $27.50, indicating a potential upside of 38.19%. Given Fulgent Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InnovAge has higher revenue and earnings than Fulgent Genetics. InnovAge is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.74	-$30.31M	-$0.09	N/A
Fulgent Genetics	$322.67M	1.70	-$60.51M	-$2.82	N/A

InnovAge has a net margin of -1.22% compared to Fulgent Genetics' net margin of -26.05%. InnovAge's return on equity of -4.73% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

InnovAge has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

12.3% of InnovAge shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 1.0% of InnovAge shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, InnovAge had 7 more articles in the media than Fulgent Genetics. MarketBeat recorded 9 mentions for InnovAge and 2 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.30 beat InnovAge's score of 1.16 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InnovAge beats Fulgent Genetics on 8 of the 15 factors compared between the two stocks.

Get Fulgent Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGT vs. The Competition

Export

Metric	Fulgent Genetics	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$547.55M	$9.83B	$7.37B	$12.85B
Dividend Yield	N/A	2.55%	2.53%	11.08%
P/E Ratio	-7.06	34.38	272.88	24.24
Price / Sales	1.70	4.97	618.96	99.81
Price / Cash	N/A	125.12	78.62	53.99
Price / Book	0.55	4.05	13.05	6.20
Net Income	-$60.51M	$311.06M	$3.47B	$348.59M
7 Day Performance	7.22%	0.83%	2.09%	0.08%
1 Month Performance	-0.40%	2.42%	6.64%	3.88%
1 Year Performance	-8.59%	15.69%	25.02%	16.98%

Fulgent Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGT Fulgent Genetics	3.6401 of 5 stars	$19.90 -0.1%	$27.50 +38.2%	-8.6%	$547.55M	$322.67M	N/A	1,315	Positive News
NEO NeoGenomics	1.417 of 5 stars	$15.90 -1.6%	$16.71 +5.1%	+156.9%	$2.04B	$727.33M	N/A	2,500
PGNY Progyny	4.6787 of 5 stars	$25.71 +1.5%	$34.10 +32.6%	+9.0%	$1.97B	$1.31B	27.95	310	News Coverage Positive News Analyst Forecast
GRDN Guardian Pharmacy Services	2.5245 of 5 stars	$38.37 +1.0%	$43.83 +14.2%	+46.7%	$1.91B	$1.46B	37.25	3,600	Analyst Upgrade
AGL Agilon Health	1.084 of 5 stars	$95.21 -1.7%	$86.18 -9.5%	+190.8%	$1.60B	$5.92B	N/A	1,076

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulgent Genetics (FLGT) Competitors

FLGT vs. NEO, PGNY, GRDN, AGL, and INNV

How does Fulgent Genetics compare to NeoGenomics?

Summary

How does Fulgent Genetics compare to Progyny?

Summary

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Summary

How does Fulgent Genetics compare to Agilon Health?

Summary

How does Fulgent Genetics compare to InnovAge?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulgent Genetics (FLGT) Competitors

FLGT vs. NEO, PGNY, GRDN, AGL, and INNV

How does Fulgent Genetics compare to NeoGenomics?

Is NEO or FLGT more profitable?

Which has more risk and volatility, NEO or FLGT?

Do analysts prefer NEO or FLGT?

Do institutionals and insiders have more ownership in NEO or FLGT?

Which has preferable earnings and valuation, NEO or FLGT?

Does the media prefer NEO or FLGT?

Summary

How does Fulgent Genetics compare to Progyny?

Which has more volatility and risk, PGNY or FLGT?

Which has stronger valuation and earnings, PGNY or FLGT?

Do insiders and institutionals have more ownership in PGNY or FLGT?

Does the media prefer PGNY or FLGT?

Do analysts prefer PGNY or FLGT?

Is PGNY or FLGT more profitable?

Summary

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Is FLGT or GRDN more profitable?

Do analysts recommend FLGT or GRDN?

Which has higher earnings and valuation, FLGT or GRDN?

Which has more risk and volatility, FLGT or GRDN?

Does the media favor FLGT or GRDN?

Do insiders & institutionals have more ownership in FLGT or GRDN?

Summary

How does Fulgent Genetics compare to Agilon Health?

Do institutionals and insiders hold more shares of FLGT or AGL?

Does the media favor FLGT or AGL?

Do analysts recommend FLGT or AGL?

Which has preferable valuation and earnings, FLGT or AGL?

Which has more risk & volatility, FLGT or AGL?

Is FLGT or AGL more profitable?

Summary

How does Fulgent Genetics compare to InnovAge?

Do analysts recommend INNV or FLGT?

Which has higher earnings & valuation, INNV or FLGT?

Is INNV or FLGT more profitable?

Which has more volatility & risk, INNV or FLGT?

Do institutionals & insiders have more ownership in INNV or FLGT?

Does the media prefer INNV or FLGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools